Raymond James downgrades Aspreva Pharmaceuticals (ASPV) to Market Perform
More News related to ASPV
- Aspreva Pharma (ASPV) Reports Q3 EPS of $0.65
- Raymond James downgrades Aspreva Pharmaceuticals (ASPV) to Market Perform
- StreetInsider.com Unusual 11 Mid-Day Movers 10/18
- StreetInsider.com Notable Mergers and Acquisitions of the Day 10/18
- StreetInsider.com Pre-Open Movers 10/18
Raymond James downgrades Aspreva Pharmaceuticals (NASDAQ: ASPV) from Outperform to Market Perform with a $26 price target.
Aspreva Pharmaceuticals is a pharmaceutical company focused on identifying, developing and commercializing existing approved drugs and drug candidates for new indications.
Related Categories
DowngradesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
